Skip to content

Decipher Genomics Resource for Intelligent Discovery

Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery (GRID)® and Data Sharing Program

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02609269
Acronym
GRID®
Enrollment
1000000
Registered
2015-11-20
Start date
2015-10-01
Completion date
2040-12-01
Last updated
2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer, Prostate Cancer, Renal Cancer

Keywords

Decipher, Transcriptome, Gene Expression

Brief summary

To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.

Detailed description

Observational study involving the release of tumor genome-wide expression and whole slide imaging data generated by the Decipher assay which will be linked to clinical treatment and outcome data for patients in whom Decipher clinical testing was performed. The GRID database population will be used to characterize the genomics and histopathologic features of cancer and discover or validate gene expression signatures as well as digital pathology models that may be useful for understanding of the biology of the disease and implementing precision medicine approaches for cancer patients.

Interventions

OTHERDecipher Cancer Classifier

The Decipher tests use gene expression-based molecular diagnostic assays that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA

Sponsors

GenomeDx Biosciences Corp
Lead SponsorINDUSTRY
Veracyte, Inc.
CollaboratorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Subjects that have had a Decipher clinical test

Design outcomes

Primary

MeasureTime frameDescription
Link complete genomic RNA expression array data generated from Decipher testing with clinical data for patients who consent to participate.Through study completion, an average of 1 yearRole of genomic expression data in the biology of certain cancers

Contacts

PRINCIPAL_INVESTIGATORElai Davicioni, PhD

Veracyte, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026